Two papers in this issue of Cell Stem Cell have made a significant advance in solving one of the great challenges of modern immunology-resurrecting thymus function through the induction of thymus epithelial cells (TECs) by directed differentiation of human embryonic stem cells (hESCs).
The thymus is a specialized immune organ that provides an inductive environment for the generation of T cells. Intriguingly, the thymus also has the unique feature of ongoing age-related atrophy beginning very early in life, albeit after cell-mediated immunity has been fully established. With the ''wear and tear'' effects of aging on the T cell pool, which are exacerbated by cytoreduction through chemotherapy, radiation, and infections such as HIV, there is an increased propensity for opportunistic infections, poor responses to vaccines, a higher incidence and burden of cancer, and an increased onset of autoimmune diseases (Heng et al., 2010) . Reestablishing thymus function thus has enormous clinical applications.
The two complementary papers by Parent et al. (2013) and Sun et al. (2013) in this issue of Cell Stem Cell tackled this challenge through the in vitro generation of TECs by directed differentiation of hESCs. They follow on from the pioneering work of Lai and Jin (2009) , who used mouse ESCs to generate functional TEC progenitors (TEPCs) capable of fully reconstituting the mouse immune system. However, it was not clear if similar results could be obtained with hESCs until now.
Both studies employed essentially similar logic to recreate in vitro the developmental pathways involved in thymus development in vivo. Using specific combinations of Wnt3A, Retinoic Acid, and BMP4, as well as inhibitors of TGF-b and canonical Wnt signaling, both induction protocols converted pluripotent hESCs to the definitive anterior foregut (Parent protocol only), the (third) pharyngeal pouch endoderm (PPE) (from which the thymus is known to originate), or both, and finally to FOXN1+ and EpCAM+ TEPCs (Figure 1 ) (Anderson et al., 2007) . Most importantly, Sun et al. were further able to demonstrate the ability of the transplanted cells to produce T cells from human HSCs.
While the induced T cultures in both studies were clearly heterogeneous, the data are consistent with the presence of thymic epithelial progenitor (or thymic epithelial progenitor-like) cells. However, it is important to note that there were no distinct indicators reflecting either cortical or medullary TEC phenotypes in culture. The TECs also lacked expression of mature markers, such as MHC class II or AIRE, which are required for the appropriate selection and self-tolerance induction of T cells. The lack of clear definition of TEPCs in these mixtures is a major unresolved issue, but collectively the data are consistent with at least some cells being committed to the TEC lineage or lineages, but only at a very immature stage of development.
The next major challenge was thus to establish the functional capacity of the TEPCs, with the expectation that their maturation would be promoted by engagement with thymocytes in vivo. Here the two studies diverged somewhat in their approaches. In the Sun study, the TEPCs were reaggregated with human embryonic fibroblasts (HEFs) as a source of mesenchymal support prior to transplantation, reflecting the need for multicellular interactions in this context. The TEPC-HEFs transplanted into athymic nude mice were able to mature in vivo, with expression of MHC class II and AIRE, but the internal thymic structures remained poorly defined. The TEPC-HEF transplants supported the development and export to the blood of mature functional T cells; however, a major lineage bias toward CD4+ T cells was observed. Importantly, analysis of the immature cells in the thymus 8-12 weeks posttransplantation indicated a severe reduction therein, suggesting that these thymuses could not sustain T cell production.
One logical explanation for the deficiencies both in thymus structure and function and the incomplete restoration of the peripheral T cell compartments is suboptimal human-mouse xenogeneic cellular and molecular interactions. In this regard, a major feature of the Sun publication was transplantation of the TEPCs into human HSC reconstituted (humanized) NOD/SCID mice. In this species-matched context, they observed similar proportions of mature CD4+ and CD8+ T cells, and importantly, a significant level of immature thymocytes, suggesting robust recruitment of the human hematopoietic T cell progenitors into the TEPC graft and their prolonged differentiation.
Using a similar TEPC reaggregated transplantation protocol into nude mice, but without exogenous fibroblast support cells, Parent et al. also showed the development of thymus-like structures. While small, disorganized, and incapable of sustaining prolonged T cell production, the structures did offer better evidence of differentiation of the TEPCs into both cortical and medullary subtypes. Again it is unclear whether these arose from a common or distinct stem/progenitor. There was also evidence of TEPC Cell Stem Cell 13, August 1, 2013 ª2013 Elsevier Inc. 135
Cell Stem Cell maturation, with induction of MHC class II, TEC markers including chemokines for attracting hematopoietic cells and the Notch signaling ligand DLL4, essential for inducing T cell commitment. Unfortunately with this protocol there was no AIRE expression in the TECs, which would predispose to autoimmunity. However, the Parent study did provide a more robust analysis of the T cells produced including proof of a broad T cell receptor (TCR) repertoire and functional capacity with respect to direct CD3/TCR crosslinking and alloresponses including rejection of skin grafts. These responses were generally not as robust as those of wildtype mouse T cells, no doubt reflecting the species mismatch.
Despite the caveats of cellular imprecision and incomplete thymus formation, these two papers represent a quantum advance in the field. The ability to generate even quasifunctional human TEPCs capable of inducing T cell production is a major milestone. It is certain to catalyze the pursuit of a more functional thymus that will sustain a diverse selftolerant T cell repertoire. Several unresolved questions remain. What accounts for the failure of the grafts to expand significantly and be maintained (suggesting that they lack capacity for selfrenewal)? Similarly, what is the phenotype of in-vitro-derived TEPCs? Do they differ in the adult? Is there a common progenitor for the cortex and medulla? Given that the transplanted TEPCs were heterogeneous, what supplementary role do the nonTEPCs play, such as the HOXA3-, EYA1-, and SIX1-expressing cells, which are linked to neural crest mesenchyme (Manley and Capecchi, 1998; Soh et al., 2009) ? Finally, are the TEPCs the primary target during aging and can they be stimulated to induce endogenous thymus regrowth?
Generating a new pool of T cells is a great achievement, but maintaining them in a state of responsiveness to foreign antigens while preventing autoimmunity is another story. These studies have thus provided a potentially important piece in the jigsaw puzzle for creating both therapeutic products and a means of inducing thymus-based tolerance to them, via complementary protocols for inducing differentiation of the same hESC line (Chidgey et al., 2008) . Which of the two approaches-de novo thymus production from pluripotential stem cells or rejuvenation of the in situ atrophic remnant-reach clinical safety and functional efficacy first remains an intriguing race. Game on. 
Figure 1. Parallel Developmental Sequences to Reach Thymic Epithelial Cells
To date, although highly promising, in vitro protocols using human ESCs have achieved TEC progenitor status-but full TEC maturation requires the multicellular and complex molecular environment in vivo.
